Translate Bio Advances Programs in Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Stock Information for Telesis Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Telesis Bio Inc.

Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
Telesis Bio Reports Third Quarter 2023 Financial Results
Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
Telesis Bio Appoints William J. Kullback Chief Financial Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.